

COVID-19 in patients treated with intravesical Bacillus Calmette Guerin

Rujittika Mungmunpantipantip^{1*} , Viroj Wiwanitkit² 

Dear Editor,

We would like to share ideas on the publication “Investigation of the frequency of COVID-19 in patients treated with intravesical BCG”. Karabay et al. concluded that “Intravesical BCG administration does not decrease the frequency of COVID-19 infection¹.” Indeed, effect of BCG on COVID-19 is an interesting issue. While some authors show that BCG might be useful, others present totally discordant ideas. A common consideration on any report of the BCG effect on COVID-19 is the confounding factor. Theoretically, by molecular mechanism via tertiary lymphoid structure (TLS) organogenesis^{2,3}, BCG might be useful. Trained immunity might occur after BCG vaccination. However, it is necessary to allow a period for immune training. From the observation by Karabay et al.¹, it might be interesting to assess time

effect. Additionally, many confounding factors can affect the observed frequency of COVID-19⁴. In the report by Karabay et al.¹, the number of subjects are also few. A larger study might give different results.

AUTHORS' CONTRIBUTIONS

RM: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. **VW:** Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing.

REFERENCES

1. Karabay O, Köse O, Tocoglu A, Uysal B, Dheir H, Yaylaci S, et al. Investigation of the frequency of COVID-19 in patients treated with intravesical BCG. *Rev Assoc Med Bras* (1992). 2020;66Suppl 2(Suppl 2):91-5. <https://doi.org/10.1590/1806-9282.66.S2.91>
2. O'Neill LAJ, Netea MG. BCG-induced trained immunity: can it offer protection against COVID-19? *Nat Rev Immunol*. 2020;20(6):335-7. <https://doi.org/10.1038/s41577-020-0337-y>
3. Koti M, Morales A, Graham CH, Siemens DR. BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy. *J Immunother Cancer*. 2020;8(2):e001119. <https://doi.org/10.1136/jitc-2020-001119>
4. Wiwanitkit V. COVID-19 death and BCG vaccination. *Tuberc Respir Dis (Seoul)*. 2021;84(1):84. <https://doi.org/10.4046/trd.2020.0115>

¹Private Academic Consultant – Bangkok, Thailand.

²Dr. D. Y. Patil University – Pune, India.

*Corresponding author: rujittika@gmail.com

Conflicts of interest: the authors declare there is no conflicts of interest. Funding: none.

Received on June 11, 2021. Accepted on July 14, 2021.

